Gefitinib for the first-line treatment of NSCLC patients with EGFR mutations in exons 19 or 21: analysis of 74 patients from Czech Republic

• Authors: SKŘIČKOVÁ Jana; BORTLÍČEK Zbyněk; HEJDUK Karel; PEŠEK Miloš; KOLEK Vítězslav; KOUBKOVÁ Leona; TOMÍŠKOVÁ Marcela; ŠATÁNKOVÁ Monika; POVOLNÁ Zdenka; ČOUPKOVÁ Helena; HAVEL Libor; ZEMANOVÁ Milada; SIXTOVÁ Dimka; SALAJKA František; HRNČIARIK Michal; ČERNOVSKÁ Markéta
• Year of publication: 2013
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine
• Description: In a group of 74 patients with advanced NSCLC and with activated mutations v/ho were treated with gefitinib in first line, the therapy was well tolerated, median progression-free survival from gefitinib treatment initiation is 8.1 months (95% CI: 6.9; 9.3) and median overall survival (OS) was not reached.